Stephen J. Gamble
Research Subjects
Stephen J. Gamble has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
Andrew Menzies
6 shared publications- David C. Wedge
Manchester Cancer Research Centre, The University of Manchester, Manchester, UK
6 shared publications Serena Nik-Zainal
6 shared publicationsStuart McLaren
6 shared publicationsDavid Jones
5 shared publicationsJohn L. Waddington
Division of Psychiatry, M.R.C. Clinical Research Centre, Northwick Park Hospital, Harrow, Middlesex HA1 3UJ, United Kingdom
5 shared publications
Latest Publications
- Open Access
- 27 May 2015
- Published by Springer Nature in Nature Genetics
- Vol. 47 (6) , 689
Erratum: Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
- 27 May 2015
- Published by Springer Nature in Nature Genetics
- Vol. 47 (6) , 689
Open AccessErratum: Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
- Top Cited PapersOpen Access
- 2 March 2015
- Published by Springer Nature in Nature Genetics
- Vol. 47 (4) , 367-372
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
Colin Cooper and colleagues report genome-wide sequences of multiple samples of multifocal cancer and morphologically normal tissue from the prostates of three men. They found high levels of mutations in morphologically normal tissue distant from the cancer, consistent with field effects. Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in morphologically normal tissue distant from the cancer, reflecting clonal expansions, and the underlying mutational processes at work in morphologically normal tissue were also at work in cancer. Our observations demonstrate the existence of ongoing abnormal mutational processes, consistent with field effects, underlying carcinogenesis. This mechanism gives rise to extensive branching evolution and cancer clone mixing, as exemplified by the coexistence of multiple cancer lineages harboring distinct ERG fusions within a single cancer nodule. Subsets of mutations were shared either by morphologically normal and malignant tissues or between different ERG lineages, indicating earlier or separate clonal cell expansions. Our observations inform on the origin of multifocal disease and have implications for prostate cancer therapy in individual cases.
- 2 March 2015
- Published by Springer Nature in Nature Genetics
- Vol. 47 (4) , 367-372
Top Cited PapersOpen AccessAnalysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue
Colin Cooper and colleagues report genome-wide sequences of multiple samples of multifocal cancer and morphologically normal tissue from the prostates of three men. They found high levels of mutations in morphologically normal tissue distant from the cancer, consistent with field effects. Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in morphologically normal tissue distant from the cancer, reflecting clonal expansions, and the underlying mutational processes at work in morphologically normal tissue were also at work in cancer. Our observations demonstrate the existence of ongoing abnormal mutational processes, consistent with field effects, underlying carcinogenesis. This mechanism gives rise to extensive branching evolution and cancer clone mixing, as exemplified by the coexistence of multiple cancer lineages harboring distinct ERG fusions within a single cancer nodule. Subsets of mutations were shared either by morphologically normal and malignant tissues or between different ERG lineages, indicating earlier or separate clonal cell expansions. Our observations inform on the origin of multifocal disease and have implications for prostate cancer therapy in individual cases.
- Top Cited Papers
- 1 August 2014
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 345 (6196) , 531
Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
Introduction: The human genome is peppered with mobile repetitive elements called long interspersed nuclear element–1 (L1) retrotransposons. Propagating through RNA and cDNA intermediates, these molecular parasites copy and insert themselves throughout the genome, with potentially disruptive effects on neighboring genes or regulatory sequences. In the germ line, unique sequence downstream of L1 elements can also be retrotransposed if transcription continues beyond the repeat, a process known as 3′ transduction. There has been growing interest in retrotransposition and 3′ transduction as a possible source of somatic mutations during tumorigenesis. Rationale: To explore whether 3′ transductions are frequent in cancer, we developed a bioinformatic algorithm for identifying somatically acquired retrotranspositions in cancer genomes. We applied our algorithm to 290 cancer samples from 244 patients across 12 tumor types. The unique downstream sequence mobilized with 3′ transductions effectively fingerprints the L1 source element, providing insights into the activity of individual L1 loci across the genome. Results: Across the 290 samples, we identified 2756 somatic L1 retrotranspositions. Tumors from 53% of patients had at least one such event, with colorectal and lung cancers being most frequently affected (93% and 75% of patients, respectively). Somatic 3′ transductions comprised 24% of events, half of which represented mobilizations of unique sequence alone, without any accompanying L1 sequence. Overall, 95% of 3′ transductions identified derived from only 72 germline L1 source elements, with as few as four loci accounting for 50% of events. In a given sample, the same source element could generate 50 or more somatic transductions, scattered extensively across the genome. About 5% of somatic transductions arose from L1 source elements that were themselves somatic retrotranspositions. In three of the cases in which we sequenced more than one sample from a patient’s tumor, we were able to place 3′ transductions on the phylogenetic tree. We found that the activity of individual source elements fluctuated during tumor evolution, with different subclones exhibiting much variability in which elements were “on” and which were “off.” The ability to identify the individual L1 source elements active in a given tumor enabled us to study the promoter methylation of those elements specifically. We found that 3′ transduction activity in a patient’s tumor was always associated with hypomethylation of that element. Overall, 2.3% of transductions distributed exons or entire genes to other sites in the genome, and many more mobilized deoxyribonuclease I (DNAse-I) hypersensitive sites or transcription factor binding sites identified by the ENCODE project. Occasionally, somatic L1 insertions inserted near coding sequence and redistributed these exons elsewhere in the genome. However, we found no general effects of retrotranspositions on transcription levels of genes at the insertion points and no evidence for aberrant RNA species resulting from somatically acquired transposable elements. Indeed, as with germline retrotranspositions, somatic insertions exhibited a strong enrichment in heterochromatic, gene-poor regions of the genome. Conclusion: Somatic 3′ transduction occurs frequently in human tumors, and in some cases transduction events can scatter exons, genes, and regulatory elements widely across the genome. Dissemination of these sequences appears to be due to a small number of highly active L1 elements, whose activity can wax and wane during tumor evolution. The majority of the retrotransposition events are likely to be harmless “passenger” mutations.
- 1 August 2014
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 345 (6196) , 531
Top Cited PapersExtensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
Introduction: The human genome is peppered with mobile repetitive elements called long interspersed nuclear element–1 (L1) retrotransposons. Propagating through RNA and cDNA intermediates, these molecular parasites copy and insert themselves throughout the genome, with potentially disruptive effects on neighboring genes or regulatory sequences. In the germ line, unique sequence downstream of L1 elements can also be retrotransposed if transcription continues beyond the repeat, a process known as 3′ transduction. There has been growing interest in retrotransposition and 3′ transduction as a possible source of somatic mutations during tumorigenesis. Rationale: To explore whether 3′ transductions are frequent in cancer, we developed a bioinformatic algorithm for identifying somatically acquired retrotranspositions in cancer genomes. We applied our algorithm to 290 cancer samples from 244 patients across 12 tumor types. The unique downstream sequence mobilized with 3′ transductions effectively fingerprints the L1 source element, providing insights into the activity of individual L1 loci across the genome. Results: Across the 290 samples, we identified 2756 somatic L1 retrotranspositions. Tumors from 53% of patients had at least one such event, with colorectal and lung cancers being most frequently affected (93% and 75% of patients, respectively). Somatic 3′ transductions comprised 24% of events, half of which represented mobilizations of unique sequence alone, without any accompanying L1 sequence. Overall, 95% of 3′ transductions identified derived from only 72 germline L1 source elements, with as few as four loci accounting for 50% of events. In a given sample, the same source element could generate 50 or more somatic transductions, scattered extensively across the genome. About 5% of somatic transductions arose from L1 source elements that were themselves somatic retrotranspositions. In three of the cases in which we sequenced more than one sample from a patient’s tumor, we were able to place 3′ transductions on the phylogenetic tree. We found that the activity of individual source elements fluctuated during tumor evolution, with different subclones exhibiting much variability in which elements were “on” and which were “off.” The ability to identify the individual L1 source elements active in a given tumor enabled us to study the promoter methylation of those elements specifically. We found that 3′ transduction activity in a patient’s tumor was always associated with hypomethylation of that element. Overall, 2.3% of transductions distributed exons or entire genes to other sites in the genome, and many more mobilized deoxyribonuclease I (DNAse-I) hypersensitive sites or transcription factor binding sites identified by the ENCODE project. Occasionally, somatic L1 insertions inserted near coding sequence and redistributed these exons elsewhere in the genome. However, we found no general effects of retrotranspositions on transcription levels of genes at the insertion points and no evidence for aberrant RNA species resulting from somatically acquired transposable elements. Indeed, as with germline retrotranspositions, somatic insertions exhibited a strong enrichment in heterochromatic, gene-poor regions of the genome. Conclusion: Somatic 3′ transduction occurs frequently in human tumors, and in some cases transduction events can scatter exons, genes, and regulatory elements widely across the genome. Dissemination of these sequences appears to be due to a small number of highly active L1 elements, whose activity can wax and wane during tumor evolution. The majority of the retrotransposition events are likely to be harmless “passenger” mutations.
- Open Access
- 1 October 2013
- Published by Springer Nature in Genome Biology
- Vol. 14 (10) , 1-14
The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models
Background: Melanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, which are frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis. Even with germline mutated p53, these engineered melanomas present with variable onset and pathology, implicating additional somatic mutations in a multi-hit tumorigenic process. Results: To decipher the genetics of these melanomas, we sequence the protein coding exons of 53 primary melanomas generated from several BRAF V600E or NRAS Q61K driven transgenic zebrafish lines. We find that engineered zebrafish melanomas show an overall low mutation burden, which has a strong, inverse association with the number of initiating germline drivers. Although tumors reveal distinct mutation spectrums, they show mostly C > T transitions without UV light exposure, and enrichment of mutations in melanogenesis, p53 and MAPK signaling. Importantly, a recurrent amplification occurring with pre-configured drivers BRAF V600E and p53 -/- suggests a novel path of BRAF cooperativity through the protein kinase A pathway. Conclusion: This is the first analysis of a melanoma mutational landscape in the absence of UV light, where tumors manifest with remarkably low mutation burden and high heterogeneity. Genotype specific amplification of protein kinase A in cooperation with BRAF and p53 mutation suggests the involvement of melanogenesis in these tumors. This work is important for defining the spectrum of events in BRAF or NRAS driven melanoma in the absence of UV light, and for informed exploitation of models such as transgenic zebrafish to better understand mechanisms leading to human melanoma formation.
- 1 October 2013
- Published by Springer Nature in Genome Biology
- Vol. 14 (10) , 1-14
Open AccessThe genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models
Background: Melanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, which are frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis. Even with germline mutated p53, these engineered melanomas present with variable onset and pathology, implicating additional somatic mutations in a multi-hit tumorigenic process. Results: To decipher the genetics of these melanomas, we sequence the protein coding exons of 53 primary melanomas generated from several BRAF V600E or NRAS Q61K driven transgenic zebrafish lines. We find that engineered zebrafish melanomas show an overall low mutation burden, which has a strong, inverse association with the number of initiating germline drivers. Although tumors reveal distinct mutation spectrums, they show mostly C > T transitions without UV light exposure, and enrichment of mutations in melanogenesis, p53 and MAPK signaling. Importantly, a recurrent amplification occurring with pre-configured drivers BRAF V600E and p53 -/- suggests a novel path of BRAF cooperativity through the protein kinase A pathway. Conclusion: This is the first analysis of a melanoma mutational landscape in the absence of UV light, where tumors manifest with remarkably low mutation burden and high heterogeneity. Genotype specific amplification of protein kinase A in cooperation with BRAF and p53 mutation suggests the involvement of melanogenesis in these tumors. This work is important for defining the spectrum of events in BRAF or NRAS driven melanoma in the absence of UV light, and for informed exploitation of models such as transgenic zebrafish to better understand mechanisms leading to human melanoma formation.
- Top Cited PapersOpen Access
- 17 June 2013
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 123 (7) , 2965-2968
Whole exome sequencing of adenoid cystic carcinoma
Adenoid cystic carcinoma (ACC) is a rare malignancy that can occur in multiple organ sites and is primarily found in the salivary gland. While the identification of recurrent fusions of the MYB-NFIB genes have begun to shed light on the molecular underpinnings, little else is known about the molecular genetics of this frequently fatal cancer. We have undertaken exome sequencing in a series of 24 ACC to further delineate the genetics of the disease. We identified multiple mutated genes that, combined, implicate chromatin deregulation in half of cases. Further, mutations were identified in known cancer genes, including PIK3CA, ATM, CDKN2A, SF3B1, SUFU, TSC1, and CYLD. Mutations in NOTCH1/2 were identified in 3 cases, and we identify the negative NOTCH signaling regulator, SPEN, as a new cancer gene in ACC with mutations in 5 cases. Finally, the identification of 3 likely activating mutations in the tyrosine kinase receptor FGFR2, analogous to those reported in ovarian and endometrial carcinoma, point to potential therapeutic avenues for a subset of cases.
- 17 June 2013
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 123 (7) , 2965-2968
Top Cited PapersOpen AccessWhole exome sequencing of adenoid cystic carcinoma
Adenoid cystic carcinoma (ACC) is a rare malignancy that can occur in multiple organ sites and is primarily found in the salivary gland. While the identification of recurrent fusions of the MYB-NFIB genes have begun to shed light on the molecular underpinnings, little else is known about the molecular genetics of this frequently fatal cancer. We have undertaken exome sequencing in a series of 24 ACC to further delineate the genetics of the disease. We identified multiple mutated genes that, combined, implicate chromatin deregulation in half of cases. Further, mutations were identified in known cancer genes, including PIK3CA, ATM, CDKN2A, SF3B1, SUFU, TSC1, and CYLD. Mutations in NOTCH1/2 were identified in 3 cases, and we identify the negative NOTCH signaling regulator, SPEN, as a new cancer gene in ACC with mutations in 5 cases. Finally, the identification of 3 likely activating mutations in the tyrosine kinase receptor FGFR2, analogous to those reported in ovarian and endometrial carcinoma, point to potential therapeutic avenues for a subset of cases.
- Top Cited PapersOpen Access
The Life History of 21 Breast Cancers
- 1 October 1989
- Published by Springer Nature in Psychopharmacology
- Vol. 99 (2) , 222-229
Social withdrawal following amphetamine administration to marmosets
Approaches and leaves from social encounters by marmosets which had received amphetamine injected either intramuscularly or into the nucleus accumbens or caudate nucleus were recorded and used to determine whether social behaviour was disrupted as a result of behavioural competition or more active social withdrawal. The social isolation observed after the marmosets had received an IM injection of amphetamine (2 mg/kg) was not due to drug-induced increases in alternative behaviours. Drugged animals immediately withdrew from social encounters, interrupting their stereotypies in order to do so, whenever they were approached by an undrugged animal. In contrast, the reduced time spent in social encounters following amphetamine injections into the nucleus accumbens (10, 20 or 40 μg) appeared to be a direct consequence of the concurrent increase in locomotion. Animals continued to initiate social encounters despite being hyperactive. Amphetamine injections into the caudate nucleus were without effect on any of the social or individual behavioural measures.
- 1 October 1989
- Published by Springer Nature in Psychopharmacology
- Vol. 99 (2) , 222-229
Social withdrawal following amphetamine administration to marmosets
Approaches and leaves from social encounters by marmosets which had received amphetamine injected either intramuscularly or into the nucleus accumbens or caudate nucleus were recorded and used to determine whether social behaviour was disrupted as a result of behavioural competition or more active social withdrawal. The social isolation observed after the marmosets had received an IM injection of amphetamine (2 mg/kg) was not due to drug-induced increases in alternative behaviours. Drugged animals immediately withdrew from social encounters, interrupting their stereotypies in order to do so, whenever they were approached by an undrugged animal. In contrast, the reduced time spent in social encounters following amphetamine injections into the nucleus accumbens (10, 20 or 40 μg) appeared to be a direct consequence of the concurrent increase in locomotion. Animals continued to initiate social encounters despite being hyperactive. Amphetamine injections into the caudate nucleus were without effect on any of the social or individual behavioural measures.
- 11 April 1985
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 42 (2) , 271-277
Cytopathogenic cerebrospinal fluid from neurological and psychiatric patients
- 11 April 1985
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 42 (2) , 271-277
Cytopathogenic cerebrospinal fluid from neurological and psychiatric patients
- Open Access
- 1 March 1985
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 48 (3) , 281
The cytopathogenic agent in CSF: evidence for a relationship with enolase levels.
- 1 March 1985
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 48 (3) , 281
Open AccessThe cytopathogenic agent in CSF: evidence for a relationship with enolase levels.